Wednesday, July 8, 2026

biotech · WHIM Syndrome · Neutropenias · XFOR

X4 Pharmaceuticals

X4 Pharmaceuticals clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

61 N Beacon St, Boston, Massachusetts 02134, US HQ
2014 Founded
81 Employees
Public company Type
XFOR · NYSE Ticker
Company details
Status
Public
HQ
61 N Beacon St, Boston, Massachusetts 02134, US
Founded
2014
Employees
81
Programs
11
Drugs
6
Patents
16
Intelligence · Clinical Programs

X4 Pharmaceuticals projects

4 ClinicalTrials.gov programs sponsored by X4 Pharmaceuticals.

X4 Pharmaceuticals has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Mavorixafor

    X4 Pharmaceuticals, Inc

    Neutropenia

    phase 3 small molecule active

    2 trials
  2. Mavorixafor

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial
  3. Mavorixafor, Mavorixafor Placebo Capsules

    X4 Pharmaceuticals, Inc

    Neutropenias

    phase 3 small molecule active

    1 trial
  4. Mavorixafor, Placebo to Test IMP

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does X4 Pharmaceuticals have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.